Patient P-02209
Therapy response
Unstable
Tolerance
Deteriorating
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
54%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S12
- Day 27 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 73 SC-12 recommended — Supportive Compound SC-12
- Day 74 Patient accepted — Started SC-12 in the companion
- Day 77 GI-04 recommended — GI Support Protocol GI-04
- Day 78 Patient accepted — Started GI-04 in the companion
- Day 80 GI symptom burden −19% vs expected — Supportive Compound SC-12
- Day 86 GI symptom burden −21% vs expected — GI Support Protocol GI-04
- Day 86 Tolerance state changed — Unstable → Improving
- Day 92 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 27.
Primary contributors, last 14 days
- Toxicity+8
- Nutritional resilience+3
- GI instability+2
What helped?
- Supportive Compound SC-12Day 73Result: symptom burden −19%
- GI Support Protocol GI-04Day 77Result: symptom burden −21%
LIFE OS recommendation
Monitoring Escalation ME-01
77%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 48
- WearableHRV 20 ms, trending down
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 37/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓65
- WearableResting HR 78 bpm
- Wearable2,647 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓30
- Daily logGI symptom score 47 and rising
- WearableSleep 6.1 h, below personal baseline
- Drug metabolism and exposure ↑20
- BloodToxicity index 42
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Rapid metabolizerExpected exposure
Microbiome
Shannon diversity 2.9 · butyrate capacity 37/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 23 ms
- Sleep
- 6.5 h
- Steps
- 2,664
- Resting HR
- 79 bpm
Daily log: GI score 47, nutritional resilience 49, adherence 52.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02244 | 42% | S14 | GI-04 | improved | 46 |
| P-02236 | 41% | S14 | GI-04 | improved | 45 |
| P-02216 | 40% | S11 | GI-04 | improved | 53 |
| P-02381 | 40% | S14 | SC-12 | improved | 52 |
| P-02508 | 40% | S14 | ME-01 | improved | 51 |
| P-02132 | 39% | S14 | SC-12 | improved | 40 |
| P-02168 | 39% | S15 | GI-04 | improved | 42 |
| P-02693 | 38% | S14 | ME-01 | improved | 41 |
| P-02255 | 37% | S14 | GI-04 | improved | 43 |
| P-02268 | 37% | S14 | GI-04 | improved | 43 |
| P-02328 | 37% | S14 | GI-04 | improved | 42 |
| P-02409 | 36% | S01 | SC-12 | no change | 54 |